scholarly journals The Preclinical Natural History of Serous Ovarian Cancer: Defining the Target for Early Detection

PLoS Medicine ◽  
2009 ◽  
Vol 6 (7) ◽  
pp. e1000114 ◽  
Author(s):  
Patrick O. Brown ◽  
Chana Palmer
2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Gautier Chene ◽  
Gery Lamblin ◽  
Karine Le Bail-Carval ◽  
Philippe Chabert ◽  
Naoual Bakrin ◽  
...  

Faced with the catastrophic prognosis for ovarian cancer due to the fact that it is most often diagnosed late at the peritoneal carcinomatosis stage, screening and early detection could probably reduce the mortality rate. A better understanding of the molecular characteristics of the different ovarian cancer subtypes and their specific molecular signatures is indispensable prior to development of new screening strategies. We discuss here the early natural history of ovarian cancer and its origins.


2016 ◽  
Vol 25 (6) ◽  
pp. 2457-2471 ◽  
Author(s):  
Serge MA Somda ◽  
Eve Leconte ◽  
Jean-Marie Boher ◽  
Bernard Asselain ◽  
Andrew Kramar ◽  
...  

Post-therapeutic surveillance is one important component of cancer care. However, there still is no evidence-based strategies to schedule patients’ follow-up examinations. Our approach is based on the modeling of the probability of the onset of relapse at an early asymptotic or preclinical stage and its transition to a clinical stage. For that we consider a multistate homogeneous Markov model, which includes the natural history of relapse. The model also handles separately the different types of possible relapses. The optimal schedule is provided by the calendar visit that maximizes a utility function. The methodology has been applied to laryngeal cancer. The different follow-up strategies revealed to be more efficient than those proposed by different scientific societies.


2018 ◽  
Vol 149 ◽  
pp. 71
Author(s):  
K.D.P. Dorayappan ◽  
R.A. Zingarelli ◽  
C.L. Hisey ◽  
B.Q. Smith ◽  
R. Wanner ◽  
...  

2018 ◽  
Vol 149 ◽  
pp. 212
Author(s):  
J. Gillen ◽  
M. Rowland ◽  
A.Y. Liu ◽  
S. Vesely ◽  
B. Powell ◽  
...  

1978 ◽  
Vol 40 (1-2) ◽  
pp. 61-109 ◽  
Author(s):  
Arthur Albert ◽  
Paul M. Gertman ◽  
Thomas A. Louis ◽  
Shu-ing Liu

1991 ◽  
Vol 8 (S2) ◽  
pp. S33-S37 ◽  
Author(s):  
T. Deckert ◽  
B. Feldt-Rasmussen ◽  
K. Borch-Johnsen ◽  
T. Jensen ◽  
A. Kofoed-Enevoldsen ◽  
...  

2019 ◽  
Vol 154 (1) ◽  
pp. e21
Author(s):  
J. Gillen ◽  
M. Enty ◽  
M. Rowland ◽  
J. Dvorak ◽  
K. Ding ◽  
...  

2021 ◽  
pp. ijgc-2021-003153
Author(s):  
Federica Sina ◽  
Chiara Cassani ◽  
Chiara Comerio ◽  
Elena De Ponti ◽  
Francesca Zanellini ◽  
...  

ObjectiveTo describe tubal histopathological abnormalities in women with germline BRCA1/2 mutations and in controls.MethodsConsecutive women with BRCA1/2 mutations undergoing bilateral salpingo-oophorectomy between 2010 and 2020 in two centers (San Gerardo Hospital, Monza and San Matteo Hospital, Pavia) were considered in this analysis and compared with controls who had the same surgical procedure for benign conditions. Frequency of p53 signature, serous tubal intraepithelial carcinoma, and high-grade serous ovarian cancer were compared between the two groups.ResultsA total of 194 women with pathogenic BRCA1/2 mutations underwent prophylactic salpingo-oophorectomy. Of these, 138 women (71%) had a completely negative histological examination, while in 56 (29%) patients an ovarian or tubal alteration was reported. Among controls, 84% of patients had a p53wt signature, while 16% had a p53 signature. There was no difference in the frequency of a p53 signature between cases and controls; however, women with BRCA1/2 mutations were more likely to have pre-malignant or invasive alterations of tubal or ovarian epithelium (p=0.015). Among mutation carriers, older age both at genetic testing and at surgery was associated with an increased risk of having malignancies (OR=1.07, p=0.006 and OR=1.08, p=0.004, respectively). The risk of malignancy seems to be increased in patients with a familial history of high-grade serous ovarian cancer. Previous therapy with tamoxifen was significantly more frequent in patients with malignant lesions (40.0% vs 21.3%, p=0.006).ConclusionWe found that a p53 signature is a frequent finding both in BRCA1/2 mutation carriers and in controls, while pre-invasive and invasive lesions are more frequent in BRCA1/2 mutation carriers. Genetic and clinical characteristics are likely to affect the progression to malignancy.


2012 ◽  
Vol 13 (12) ◽  
pp. 13352-13377 ◽  
Author(s):  
Vladimir Kashuba ◽  
Alexey A. Dmitriev ◽  
George S. Krasnov ◽  
Tatiana Pavlova ◽  
Ilya Ignatjev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document